
Uppsala Reports editor
@UMCGlobalSafety
Photo by Pau Casals on Unsplash
In the new episode of the Drug Safety Matters podcast, explore the problem of the data we don't see and find out what can be done to peel back the curtain.
Clinical trials are the “gold standard” of evidence-based medicine – the best way we have to test whether a drug is safe and effective before it enters the market. But if trial data is poorly reported or – even worse – left unpublished, how are we supposed to determine the true value of a medical treatment?
Peter Doshi, associate editor at The BMJ and founder of the Restoring Invisible and Abandoned Trials (RIAT) Support Center, has made it his mission to fix the problem and improve data transparency for good.
Subscribe by visiting the Drug Safety Matters website or listen in right here:
Learn more
To find out a lot more about Peter Doshi and his work, be sure to visit the RIAT Support Center here.
Peter Doshi on Drug Safety Matters. Photo: UMC
Uppsala Monitoring Centre (UMC), the WHO Collaborating Centre for International Drug Monitoring, is pleased to announce the arrival of its new director Peter Hjelmström.
Communications / 06 March 2023
UMC pays homage to a trailblazer in pharmacovigilance, Dr. Ed Napke.
Communications / 14 March 2023
We pay tribute to the life of a true advocate and agent of change in patient and medicines safety, Barbro Westerholm, who has died age 89.
Communications / 11 April 2023